Casma Therapeutics to Present at the UBS Virtual Biotechnology Private Company Symposium

September 15, 2021

CAMBRIDGE, Mass., September 15, 2021 – Casma Therapeutics, Inc., a biotechnology company harnessing the process of autophagy to design powerful new medicines, today announced that Keith Dionne, Ph.D., Chief Executive Officer of Casma, will participate in the upcoming virtual UBS Virtual Biotechnology Private Company Symposium being held on September 22-23, 2021.

UBS Virtual Biotechnology Private Company Symposium
Date: Wednesday, September 22^nd
Time: 9:00 a.m. ET

About Casma Therapeutics

Casma Therapeutics is harnessing autophagy by developing a novel degradation technology to open new target areas for drug discovery and development that will profoundly impact the lives of patients. Autophagy is a conserved cellular process that contributes to overall organismal health, but when autophagy is perturbed, inefficient autophagic flux contributes to numerous diseases. By selectively boosting autophagy and degradation of disease targets in the lysosome, Casma expects to be able to arrest or reverse the progression of several diseases such as neurodegeneration, metabolic disorders, inflammation and muscle degeneration. For more information, please visit www.casmatx.com.

Contact

Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@sternir.com

Back to news & media

Keep reading:

News June 5, 2025
Casma Therapeutics Nominates CSM-101 as a Development Candidate for the Treatment of Rare and Common Forms of Parkinson’s Disease

Casma’s first-in-class TRPML1 agonist represents a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases CAMBRIDGE, Mass., June 5, 2025 — Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, CSM-101, a first-in-class TRPML1 agonist. […]
News April 17, 2024
Casma Therapeutics to Participate at 23rd Annual Needham Virtual Healthcare Conference and at UBS Virtual Targeted Protein Degradation Day

CAMBRIDGE, Mass., April 17, 2024 – Casma Therapeutics, Inc., a biotechnology company engaging the autophagy/lysosomal system to provide innovative new medicines, today announced that Frank Gentile, PhD, Chief Executive Officer, presented and participated in one-on-one meetings at the 23rd Annual Needham Virtual Healthcare Conference on April 5, 2024. Frank Gentile, PhD, will also attend and participate in […]